BioSpace News Archive

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC).

Rilas Technologies, Inc (Rilas) is announcing that it will be moving to a larger facility this fall where Rilas will expand its current purification and analytical capabilities...

The development of innovative biochips is aimed at increasing speed of medical processes, simplifying many complex procedures, and reducing the overall costs.

At the same time, rise in product approvals by the respective bodies and increase in healthcare expenditure across the world have supplemented the market growth yet more.

ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, reported 2021 financial results and provided a corporate update.

Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2022 and provided a business update on recent corporate and operational developments.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs.

Vor Bio, a clinical-stage cell and genome engineering company, reported financial results for the three-month period and full year ended December 31, 2021, and provided a business update.

Travere Therapeutics, Inc. announced that on March 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,000 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 33,000 shares of its common stock.